Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALENTOP: Hepatic Resection After Atezolizumab Plus Bevacizumab in HCC With Venous Thrombosis
NCT04649489Phase 3Active, not recruiting
- Start
- Apr 2021
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in hepatocellular carcinoma (HCC) (2 arms). Primary endpoint: Time to Treatment Failure at 24 months. Started Apr 2021; status: active, not recruiting.
02
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04649489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04649489.